WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014200325) CONSORTIUM OF THE RECOMBINANT INFLUENZA A VIRUSES FLU-NS1-124- L7/L12-H5N1, FLU-NS1-124-OMP16-H5N1, FLU-NS1-124-L7/L12-H1N1 AND FLU-NS1- 124-OMP16-H1N1, FAMILY ORTOMYXOVIRIDAE, GENUS INFLUENZAVIRUS, EXPRESSING BRUCELLA IMMUNODOMINANT PROTEINS DESTINED TO GENERATE A VACCINE AGAINST BRUCELLOSIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/200325    International Application No.:    PCT/KZ2014/000006
Publication Date: 18.12.2014 International Filing Date: 23.05.2014
IPC:
A61K 39/02 (2006.01), A61K 39/00 (2006.01)
Applicants: THE REPUBLICAN GOVERNMENT ENTERPRISE ON THE BASIS OF ECONOMIC CONTROL RIGHTS "RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS" OF THE SCIENCE COMMITTEE OF THE MINISTERY OF EDUCATION AND SCIENCE OF THE REPUBLIC OF KAZAKHSTAN [KZ/KZ]; Gvardeiskiy Kordaiskiy region Zhambylskaya obl., 080409 (KZ)
Inventors: SANSYZBAY, Abylay Rysbayuly; .
TABYNOV, Kaisar Kazybayevich; .
YESPEMBETOV, Bolat Amanbayevich; .
SULTANKULOVA, Kulyaisan Turlybayevna; .
KHAIRULLIN, Berik Mikhitovich; .
SANDYBAYEV, Nurlan Tamambayevich; .
YEGOROV, Andrei Yur'yevich;
Priority Data:
2013/0790.1 14.06.2013 KZ
Title (EN) CONSORTIUM OF THE RECOMBINANT INFLUENZA A VIRUSES FLU-NS1-124- L7/L12-H5N1, FLU-NS1-124-OMP16-H5N1, FLU-NS1-124-L7/L12-H1N1 AND FLU-NS1- 124-OMP16-H1N1, FAMILY ORTOMYXOVIRIDAE, GENUS INFLUENZAVIRUS, EXPRESSING BRUCELLA IMMUNODOMINANT PROTEINS DESTINED TO GENERATE A VACCINE AGAINST BRUCELLOSIS
(FR) CONSORTIUM DES VIRUS D'INFLUENZA A FLU-NSI-124-L7/L12-H5N1, FLU-NSI-124-OMP16-H5N1, FLU-NSI-124-L7/L12-H1N1 ET FLU-NSI-124-OMP16-H1N1 RECOMBINÉS, FAMILLE DES ORTHOMYXOVIRIDAE, GENRE VIRUS INFLUENZA, EXPRIMANT LES PROTÉINES IMMUNODOMINANTS DE BRUCELLA DESTINÉ À GÉNÉRER UN VACCIN CONTRE LA BRUCELLOSE
Abstract: front page image
(EN)This invention relates to the fields of biotechnology, veterinary science and public health, and describes a vector vaccine which can be used to prevent brucellosis. The essence of the invention is that reverse genetics methods have been used to construct novel, genetically-stable recombinant influenza viral vectors based on the influenza A viral vectors Flu-NSl-124-L7/L12- H5N1, Flu-NSl-124-Omp16-H5Nl, Flu-NSl-124-L7/L12-HlNl and Flu-NSl-124-Omp16- H1N1 (of the subtypes H5N1 and H1N1) that contain the genetic sequences of the Brucella proteins L7/L12 (ribosomal) or Omp16 (outer membrane) inserted into the viral NS1 gene, which express these Brucella proteins in vivo and are safe in cattle. Our studies showed that this vaccine candidate in cattle induced a strong antigen-specific T-cell immune response, and most importantly provided a high level of protectiveness comparable to the commercial B. abortus S19 vaccine and superior to the B. abortus S19 vaccine in combination with Montanide Gel01 adjuvant. Furthermore it is shown that the developed vaccines can effectively differentiate vaccinated animals from infected animals.
(FR)Cette invention concerne les domaines de la biotechnologie, de la science vétérinaire et de la santé publique, et décrit un vaccin vectoriel qui peut être utilisé pour prévenir la brucellose. L'essence de cette invention est que des méthodes de génétique inverse ont été utilisées pour construire de nouveaux vecteurs viraux grippaux recombinés, génétiquement stables basés, sur les vecteurs viraux Flu-NSl-124-L7/L12- H5N1, Flu-NSl-124-Omp16-H5Nl, Flu-NSl-124-L7/L12-HlNl et Flu-NSl-124-Omp16-H1N1 (des sous-types H5N1 et H1N1) de l'influenza A qui contiennent les séquences génétiques des protéines L7/L12 (ribosomales) ou Omp16 (membrane extérieure) de Brucella insérées dans le gène viral NS1, qui expriment ces protéines de Brucella in vivo et sont sans danger chez le bétail. Nos études ont montré que ce vaccin candidat a induit chez le bétail une forte réponse immunitaire en cellules T spécifiques de l'antigène, et plus important, ont conféré un niveau élevé de protection comparable au vaccin commercial anti-B. abortus S19 et supérieur au vaccin anti-B. abortus S19 en combinaison avec l'adjuvant Montanide Gel01. Il est en outre démontré que les vaccins mis au point peuvent efficacement différencier les animaux vaccinés des animaux infectés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)